Glioblastoma — Phase 1 trials
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 2 Study of HX301 in Patients with High-grade Giloma
HX301+/Temozolomide — 1 site
- TRIALPHASE1ENROLLING_BY_INVITATION
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Nivolumab · Azacitidine (AZA) · lumbar puncture — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Pembrolizumab · Stereotactic Radiation Therapy · Surgical Resection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debio 0123 · Temozolomide · Radiotherapy — 16 sites
- TRIALPHASE1 / PHASE2RECRUITING
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Biospecimen Collection · Eflornithine · Lumbar Puncture — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Trametinib and Nivolumab · Dabrafenib, trametinib, nivolumab — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALPHASE1RECRUITING
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
ERAS-801 · ABBV-637 · ABBV-155 — 11 sites
- TRIALPHASE1RECRUITING
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
NK-92/5.28.z · Ezabenlimab — 5 sites
- TRIALPHASE1RECRUITING
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
15.GPC3-CAR T cells — 1 site
- TRIALPHASE1RECRUITING
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Atovaquone · Radiation Therapy — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Intra-arterial Cetuximab · Intra-arterial Mannitol — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
Temozolomide · CIK
- TRIALPHASE1 / PHASE2RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
TGX-007 · Valaciclovir — 2 sites
- TRIALPHASE1RECRUITING
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells · Biopsy Procedure · Biospecimen Collection — 1 site
- TRIALPHASE1RECRUITING
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Anti-GARP Chimeric Antigen Receptor-T Cells · Biospecimen Collection · Chest Radiography — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
MR-Linac System · Radiation Therapy · Temozolomide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Near-Infrared Fluorescence Imaging · Panitumumab · Panitumumab-IRDye800 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE1 / PHASE2RECRUITING
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
ADV/HSV-tk (gene therapy) — 1 site
- TRIALPHASE1RECRUITING
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
NK Cells · NK Cells — 1 site
- TRIALPHASE1RECRUITING
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus · Trametinib — 17 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
BEY1107 · Temozolomide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Tarlatamab · Concurrent Radiation Therapy · Sequential Radiation therapy — 2 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
MSC11FCD — 1 site
- TRIALPHASE1RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-1255 Dose Escalation · RSC-1255 Dose Expansion — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Olaparib; 177Lu-DOTATATE — 1 site
- TRIALPHASE1RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Dual-target CAR-NK cells · Cyclophosphamide · Fludarabine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Capecitabine · Temozolomide — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.